


10/088369

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1987:598314 CAPLUS
DN 107:198314
TI Preparation of [(3-aminopropoxy)phenyl]thienoisoxazoles and- pyrazoles
for treatment of hypertension and glaucoma
IN Ong, Helen Hu; Yasenchak, Christine Mary
PA Hoechst-Roussel Pharmaceuticals, Inc., USA
SO Eur. Pat. Appl., 73 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 221414	A1	19870513	EP 1986-114314	19861016
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4728651	A	19880301	US 1985-791019	19851024
DK 8605079	A	19870425	DK 1986-5079	19861023
AU 8664337	A1	19870430	AU 1986-64337	19861023
JP 62103086	A2	19870513	JP 1986-250937	19861023
ZA 8608065	A	19870624	ZA 1986-8065	19861023
HU 45061	A2	19880530	HU 1986-4456	19861023
HU 198058	B	19890728		
US 4769472	A	19880906	US 1987-125108	19871125
PRAI US 1985-791019	A	19851024		
OS CASREACT 107:198314				
GI				




AB The title compds. [I; X = O, NR; R = H, alkyl; R1 = H; R2 = alkyl, arylalkyl, aryloxyalkyl, indolylalkyl, benzodioxarylalkyl, or NR¹R² = (arylalkyl)piperazinyl] were prepared as antihypertensives and for reduction of intraocular pressure. 3-[(2-Epoxymethoxy)phenyl]-1-methyl-1H-thieno[3,2-c]pyrazole 3 g was refluxed with Me₃CNH₂ in EtOH for 5 h to give 2.5 g of [(aminopropoxy)phenyl]thienopyrazole derivative (II).2HCl. II reduced outflow pressure by 51% when administered to an eye as a 2% solution


IT 110894-42-3P 110894-43-4P 110894-44-5P
110894-46-7P 110894-49-0P 110894-50-3P
110894-51-4P 110894-52-5P 110894-53-6P
110894-59-2P 110894-60-5P 110894-61-6P
110894-62-7P 110894-63-8P 110894-64-9P
110894-65-0P 110894-66-1P 110894-76-3P
110916-52-4P

10/088369


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for treatment of hypertension and glaucoma)
RN 110894-42-3 CAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-43-4 CAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)




RN 110894-44-5 CAPLUS
CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-46-7 CAPLUS
CN 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)

10/088369




RN 110894-49-0 CAPLUS

CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-43-4

CMF C17 H20 N2 O3 S




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 110894-50-3 CAPLUS


CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-42-3

CMF C18 H22 N2 O3 S


10/088369




CM 2

CRN 110-16-7
CMF C₄ H₄ O₄

Double bond geometry as shown.




RN 110894-51-4 CAPLUS
CN 2-Propanol,
1-[(1-methyl-3-phenylpropyl)amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)-(9CI) (CA INDEX NAME)



RN 110894-52-5 CAPLUS
CN 2-Propanol, 1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)-, hydrochloride (9CI) (CA INDEX NAME)

10/088369




● HCl

RN 110894-53-6 CAPLUS

CN 2-Propanol,


1-[(2-(1H-indol-3-yl)ethyl)amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 110894-59-2 CAPLUS

CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(3-thieno[2,3-b]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)




RN 110894-60-5 CAPLUS

CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(3-thieno[2,3-b]isoxazol-3-ylphenoxy)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

10/088369

CM 1


CRN 110894-59-2
CMF C17 H20 N2 O3 S




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 110894-61-6 CAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-(3-thieno[2,3-d]isoxazol-4-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110894-62-7 CAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-(3-thieno[2,3-d]isoxazol-4-ylphenoxy)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-61-6
CMF C18 H22 N2 O3 S




10/088369


CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 110894-63-8 CAPLUS
CN 2-Propanol, 1-[(2-(3,4-dimethoxyphenyl)ethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-ylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 110894-64-9 CAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(4-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)




RN 110894-65-0 CAPLUS
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-(4-thieno[2,3-d]isoxazol-3-ylphenoxy)-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 110894-64-9
CMF C17 H20 N2 O3 S


10/088369




CM 2

CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



RN 110894-66-1 CAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-(4-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)




RN 110894-76-3 CAPLUS
CN 2-Propanol, 1-[[[2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)



RN 110916-52-4 CAPLUS
CN 2-Propanol,
1-[(2-(1H-indol-3-yl)ethyl)amino]-3-(2-thieno[2,3-d]isoxazol-3-ylphenoxy)- (9CI) (CA INDEX NAME)

10/088369



10/088369

=> d l1; d his; log y
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


(FILE 'HOME' ENTERED AT 11:23:32 ON 18 FEB 2005)

FILE 'REGISTRY' ENTERED AT 11:23:40 ON 18 FEB 2005
L1 STRUCTURE uploaded
L2 8 S L1
L3 214 S L1 FUL

FILE 'CAPLUS' ENTERED AT 11:24:23 ON 18 FEB 2005
L4 3 S L3

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.72	177.26
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.19	-2.19

STN INTERNATIONAL LOGOFF AT 11:25:22 ON 18 FEB 2005



chain nodes :

15 16 17 18 27 36 37 38 41 42 43 44

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 22 23 24 25 26 28 29
30 31 32 33

ring/chain nodes :

19 45

chain bonds :

3-9 15-16 17-18 18-19 26-27 27-28 36-37 37-38 41-42 42-43 42-44
42-45

ring bonds :

1-2 1-5 1-6 2-3 2-8 3-4 4-5 6-7 7-8 9-10 9-14 10-11 11-12
12-13 13-14 22-23 22-26 23-24 24-25 25-26 28-29 28-33 29-30
30-31 31-32 32-33

exact/norm bonds :

1-2 1-5 1-6 2-3 2-8 3-4 4-5 6-7 7-8 15-16 18-19 22-23 22-26
23-24 24-25 25-26 26-27 27-28 37-38 41-42 42-43 42-44

exact bonds :

3-9 17-18 36-37 42-45

normalized bonds :

9-10 9-14 10-11 11-12 12-13 13-14 28-29 28-33 29-30 30-31 31-32
32-33

G1:X, [*1]

G2: [*2], [*3], [*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:CLASS
28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 36:CLASS 37:CLASS
38:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS 45:CLASS 52:CLASS